Company / Return on Equity (ROE)
Verrica Pharmaceuticals Inc. Return on Equity (ROE) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-339.0%
FY2024
5-year range
-339.0% / -61.2%
FY2021-FY2024
Trend
-454.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Verrica Pharmaceuticals Inc. reports negative total equity of -339.0% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-339.0% in FY2024 with a 3-year CAGR of -209.6%.
Declined from -107.6% to -339.0% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -209.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, return on equity (roe) decreased 454.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score -3.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -339.0% | -454.2% |
| FY2023 | -61.2% | +43.1% |
| FY2022 | -107.6% | +16.9% |
| FY2021 | -129.4% | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026